Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 1.7% – Time to Sell?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s share price traded down 1.7% during trading on Tuesday . The company traded as low as $11.21 and last traded at $11.74. 367,725 shares traded hands during trading, a decline of 77% from the average session volume of 1,570,210 shares. The stock had previously closed at $11.94.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on Tonix Pharmaceuticals in a research note on Monday. They set a “sell” rating for the company.

Tonix Pharmaceuticals Stock Performance

The business has a 50 day moving average of $29.49 and a 200 day moving average of $25.62. The company has a market capitalization of $22.15 million, a P/E ratio of 0.00 and a beta of 2.07. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($23.00) earnings per share (EPS) for the quarter, beating the consensus estimate of ($203.00) by $180.00. The business had revenue of $2.82 million during the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. On average, sell-side analysts predict that Tonix Pharmaceuticals Holding Corp. will post -1762.5 earnings per share for the current year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. Commonwealth Equity Services LLC acquired a new stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 120,292 shares of the company’s stock, valued at approximately $40,000. Commonwealth Equity Services LLC owned about 6.43% of Tonix Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.